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Hundreds of genomes have been successfully sequenced to date, and the data are publicly available. At
the same time, the advances in large-scale expression and puriﬁcation of recombinant proteins have
paved the way for structural genomics efforts. Frequently, however, little is known about newly
expressed proteins calling for large-scale protein characterization to better understand their biochemical
roles and to enable structure–function relationship studies. In the Structural Genomics Consortium (SGC),
we have established a platform to characterize large numbers of puriﬁed proteins. This includes screen-
ing for ligands, enzyme assays, peptide arrays and peptide displacement in a 384-well format. In this
review, we describe this platform in more detail and report on how our approach signiﬁcantly increases
the success rate for structure determination. Coupled with high-resolution X-ray crystallography and
structure-guided methods, this platform can also be used toward the development of chemical probes
through screening families of proteins against a variety of chemical series and focused chemical libraries.
 2010 Elsevier Inc. Open access under CC BY license.1. Introduction
With genome projects coming to completion almost a decade
ago (Lander et al., 2001; McPherson et al., 2001; Venter et al.,
2001; Waterston et al., 2002), and many similar breakthroughs in
structure determination techniques and instrumentation, large-
scale structure determination efforts were initiated (Burley et al.,
1999; Christendat et al., 2000; Edwards et al., 2000; Gaasterland,
1998; Montelione and Anderson, 1999; Terwilliger et al., 1998;
Vitkup et al., 2001). Such efforts led to the creation of many struc-
tural genomics groups that in time proved to be very efﬁcient in
high throughput protein structure determination (Edwards, 2009;
Terwilliger et al., 2009). However, solving the structures of some
proteins has been more challenging than others because of the
diversity among proteins and their physical properties.
The production of proteins in a soluble form suitable for crystal-
lization or nuclear magnetic resonance (NMR) studies has been a
key element in structural genomics efforts. Attempting protein
expression from different expression vectors or host cells and
expression of domains or truncated proteins can signiﬁcantly
increase the probability of obtaining soluble and crystallizable pro-
teins (Graslund et al., 2008; Lesley and Wilson, 2005; Vedadi et al.,
2007). However, many proteins or domains remain unstable orVedadi).
 license.partially soluble, often because they lack the appropriate cofactors
or stabilizing ligands, or they are not in an optimum buffer condi-
tion. The presence of ligands often helps in obtaining well-diffract-
ing crystals in such cases (Fedorov et al., 2007; Vedadi et al., 2006).
Nevertheless, structural genomics efforts have led to the depo-
sition of thousands of structures, with an average of more than 150
structures per year from each of the major initiatives (Terwilliger
et al., 2009). The functions of many of these proteins are either un-
known or have been inferred from amino acid sequences. In the
case of enzymes, little is often known about their substrate speci-
ﬁcities. The identiﬁcation of natural ligands (including peptide li-
gands) can help identify the native biochemical functions of
proteins with unknown functions (Carver et al., 2005). High afﬁn-
ity, synthetic ligands can also serve as excellent research tools to
investigate a protein’s function and speciﬁcity in a cellular context.
Importantly, such efforts require an active, puriﬁed protein - a
resource that is not trivial to produce, but is one that comprises
the core of all structural genomics efforts. Ligand screening is a
synergistic effort that facilitates both protein structural elucidation
as well as the discovery of new functional information.
In the Structural Genomics Consortium (SGC, www.thesgc.org),
we have established a high throughput platform using a 384-well
format to characterize human proteins that includes screening
the proteins against a variety of chemical series and focused chem-
ical libraries, as well as investigating their binding and catalytic
speciﬁcities. This platform includes thermodenaturation-based
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differential static light scattering (DSLS), enzyme assays, an ampli-
ﬁed luminescence proximity homogeneous assay (AlphaScreen),
peptide arrays, a peptide displacement assay using ﬂuorescence
polarization, and dynamic light scattering (DLS) (Fig. 1).
Although there are other methods that can be used in the bio-
physical characterization of recombinant proteins, in this review
we focus on the SGC platform and its application toward facilitating
structure determination of large numbers of eukaryotic proteins,
especially human protein families. We discuss its application, cou-
pled with high-resolution X-ray crystallography and structure-
guided methods, toward the development of chemical probes to
proteins that are involved in a variety of post-translationalmodiﬁca-
tions of histones, which in turn affect gene expression.
2. Screening for ligands using thermodenaturation-based
techniques
Enzyme activity-based screening has long been used for high
throughput compound screening. However, developing an enzyme
assay for each protein is time consuming and may take several
weeks or months. Alternative methods are also needed for non-en-
zyme targets. Many methods can detect ligand binding, but they
may not be applicable for high or medium throughput screening.
Isothermal titration calorimetry (ITC) is now widely used to detect
protein interactionwith compounds (Bains and Freire, 1991; Bundle
and Sigurskjold, 1994; Chaires, 2008; Cooper and Johnson, 1994;
Velazquez-Campoy et al., 2004; Velazquez Campoy and Freire,
2005). This method is reliable in determining KD values for com-
pounds, and it also provides a complete thermodynamic proﬁle of
ligand binding. However, it is a low throughput method and
requires relatively high amounts of protein and ligand. Recently,Purified Prote
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the structure–function relationship.miniaturized ITC units with reduced sample volumes (approxi-
mately 200 ll) have been developed, but these still require consid-
erable amounts of protein, and each run may take about two hours
to complete. Although not an option for screening high numbers of
compounds, ITC is perhaps themost reliable technique for the quan-
titative measurement of ligand binding to a soluble protein.
Surface plasmon resonance (SPR) is another widely-used meth-
od for detecting protein–ligand interaction (Malmqvist, 1999; Rich
and Myszka, 2000). This method uses biosensors to measure the
change in the refractive index of the solvent near the surface of
the sensor that occurs during complex formation or dissociation.
The instruments are capable of characterizing binding reactions
in real-time without labeling requirements. Consequently, SPR bio-
sensors can be used to study the interactions of proteins and other
biological systems. The method requires the immobilization of bio-
molecules to the surface of the sensor. The information obtained by
SPR is both qualitative and quantitative, and it is suitable for mea-
suring binding afﬁnity (Karlsson, 2004). The advantage of SPR over
ITC is that it requires less protein, and several samples can be pro-
cessed simultaneously. The disadvantage is that one of the system
components has to be immobilized on the surface of the sensor. ITC
provides a direct measurement of the enthalpy of binding (DH),
while in the case of SPR the binding constants have to be measured
at several temperatures to obtain the enthalpy (Navratilova et al.,
2007). Comparative studies show good correlations between the
thermodynamic data obtained by SPR and ITC (Day et al., 2002;
Navratilova et al., 2007).
The stabilization of proteins upon ligand binding is well
documented in the literature (Brandts and Lin, 1990; Pace and
McGranth, 1980; Schwarz, 1988). The coupling of the energies of
ligand binding and protein unfolding results in ligand-dependent
changes in the thermal stability of the protein–ligand complexin
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Pantoliano et al., 2001). When the proteins are heated at a constant
rate, it is possible to monitor unfolding and plot the signal as a
function of temperature to obtain a sigmoidal curve representing
the fraction of unfolded protein. The inﬂection point is usually re-
ferred to as the melting temperature (Tm) where 50% of the protein
is unfolded (Lo et al., 2004; Pantoliano et al., 2001). Upon ligand
binding, the protein denatures at a higher temperature, and the
difference in the Tm values in the presence and absence of the com-
pound (DTm) reﬂects ligand binding. In the SGC, we use both ﬂuo-
rescence- (DSF) and aggregation-based (DSLS) thermodenaturation
monitoring methods (Fig. 2) (Niesen et al., 2007; Senisterra et al.,
2006; Vedadi et al., 2006). These are alternative ligand binding
detection methods that are not dependent on protein function
and can be employed for screening the majority of proteins in a
384-well format without the need for customization or assay
development. Other methods, such as circular dichroism (CD)
and differential scanning calorimetry (DSC), can also be used to as-
sess protein thermodenaturation and ligand binding. However,
both are low throughput methods.
Circular dichroism spectra provide an index of structure in pro-
teins, and changes in the CD spectra may reﬂect perturbation of the
structure. Therefore, folding and unfolding of a protein and the re-
sponse to binding of a ligand can be monitored by CD spectroscopy.
Heat-denaturation of proteins can be followed by monitoring the
decrease in ellipticity at 220 nm as the temperature is increased,
for example, from 25 to 85 C (Chen et al., 1999; Epand and Epand,
2003; Narhi et al., 1999; Swint and Robertson, 1993). The pattern
of the thermodenaturation proﬁles of proteins obtained by CD is
similar to that obtained from DSLS and DSF. Proﬁling the stability
of many proteins in parallel by CD and DSLS/DSF shows that these
methods provide similar data (Allali-Hassani et al., 2009; Vedadi et
al., 2006). Differential scanning calorimetry (DSC) is also useful for
the study of heat-initiated phase changes in proteins and gives
measurements of DH and other thermodynamic parameters of
unfolding, ligand binding and complex formation. However, the40 50 60 70 80
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Fig. 2. Detecting ligand binding using thermodenaturation. The effect of nucleo-
tides on human GDP-D-mannose 4,6-dehydratase (GMD) was investigated by
screening the protein both in the absence of any compound (D, control) and in the
presence of 5 mM NAD+ (x), 5 mM NADH (.), 1 and 5 mM NADP+ (s and d
respectively), 1 and 5 mM NADPH (h and j respectively), and 10 mM GDP ().
NADP+, NADPH and GDP stabilized GMD in a concentration-dependent manner,
indicating that these compounds bind to GMD, whereas NAD+ and NADH did not
have any effect (no binding). This is an example illustrating that the thermodena-
turation methods can easily be used to investigate binding speciﬁcity of proteins.
Abbreviations: GDP: guanosine diphosphate, NAD/NADH: nicotinamide adenine
dinucleotide, NADP/NADPH: nicotinamide adenine dinucleotide phosphate.throughput is low and it is not convenient for screening a large
number of compounds. ATLAS™ (Any Target Ligand Afﬁnity
Screen) is another thermal denaturation based method that detects
thermally unfolded and aggregated hexahistidine-tagged proteins.
This method uses time-resolved ﬂuorescence resonance energy
transfer between two anti- hexahistidine antibodies, labeled with
either a donor or acceptor ﬂuorophore, that are simultaneously
bound to the hexahistidine tags of aggregated protein (Patel et
al., 2008; Thompson et al., 2008). Although this method is used
in a 384-well format, it requires assay optimization for each pro-
tein (such as optimizing incubation temperature and time, and
protein concentration) and some proteins with high Tm may not
be amenable to this assay. Also presence of any aggregation in pro-
tein solution prior to heating increases the background and multi-
ple heating and cooling cycles are needed to generate data points
at different temperature.
In the differential scanning ﬂuorimetry (DSF) method, external
ﬂuorescent probes are used to detect changes in protein surface
hydrophobicity in a 384-well format. The ﬂuorescence properties
of these probes are quenched by water in aqueous solutions. How-
ever, in a hydrophobic environment introduced by protein unfold-
ing during heat-denaturation, the ﬂuorescence signal will increase
(Epps et al., 2001; Slavik et al., 1982). The signal can be moni-
tored using a variety of plate readers, including RT-PCR devices
(Mx3005p™ fromStratagene, iCycler fromBio-Rad andLightCycler
480 II from Roche) and ﬂuorescence plate readers such as FluoDia
T70 from PTI (Fedorov et al., 2007; Niesen et al. 2007; Vedadi et
al., 2006). The ﬁrst probe used for this purpose was 1-anilinonaph-
thalene-8-sulfonate (ANS), as reviewed previously (Slavik et al.,
1982). Other probes with higher ﬂuorescence quantum yields were
later described (Epps et al., 2001). To date, the dye with the most
favorable properties for DSF is SYPRO orange, owing to its high
signal-to-noise ratio (Niesen et al., 2007). Alexandrov et al., have
recently reported the use of the thiol-speciﬁc ﬂuorochrome N-[4-
(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM)
for stability proﬁling of membrane proteins (Alexandrov et al.,
2008). The method uses the chemical reactivity of the native cyste-
ines embedded in the protein interior as a sensor for the overall
integrity of the folded state. Upon temperature-induced unfolding,
CPM, which is nonﬂuorescent in the unbound form, reacts with
the exposed cysteine residues, and an increase in its ﬂuorescence
intensity can be monitored. Some soluble proteins also have acces-
sible hydrophobic areas and, therefore, their thermodenaturation
cannot be monitored by using reporter dyes such as Sypro Orange
that ﬂuoresce in hydrophobic environments. In a case study, more
than25%of 60 solubleproteins examinedbyDSFusing SyproOrange
were not amenable to such screening, partly due to a high ﬂuores-
cence background (Fig. 3) (Vedadi et al., 2006). In comparison using
CPM, the signal-to-noise ratio is higher for such proteins during
thermodenaturation, and it may allow reliable Tm measurements
(Fig. 4). However, the CPM method is only applicable to proteins
with embedded cysteine residues. The analysis of PDB archive by
Alexandrov et al., also showed that about a third of the membrane
proteins do not have any embedded cysteine residues, and about
9% of the existing cysteine residues are not embedded in the protein
interior. However, it might be possible to introduce cysteine resi-
dues by mutation without compromising the protein structural
integrity to enable such measurements for ligand screening. They
performed the assays successfully for several membrane proteins
using a Cary Eclipse spectroﬂuorometer, which allows simultaneous
analysis of four samples. We also employed this protocol in the SGC
in a 96-well plate using the Mx3005p™ from Stratagene (ex;
350 nm, em: 516 nm) to assess the thermodenaturation of human
pantothenate kinases (PANK3; Fig. 4) and obtained a typical ther-
modenaturation proﬁle. Our results indicate that, although PANK3
is not amenable to DSF using Sypro Orange as the reporter dye due
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Fig. 3. Examples of DSF proﬁles using SYPRO Orange as a reporter dye. The majority of proteins (>70%, (Vedadi et al. 2006)) are amenable to DSF using SYPRO Orange.
Although many proteins may show perfect transitions with low ﬂuorescence backgrounds (A), some may cause higher initial backgrounds with strong (B) or weak (C)
transitions. Some proteins may not be amenable to DSF using SYPRO Orange due to high initial ﬂuorescence backgrounds (D). Following the peak of intensity, a gradual
decrease is observed, which is mainly due to the removal of protein from the solution due to aggregation and precipitation. A similar pattern can also be observed for
thermodenaturation proﬁles obtained by DSLS.
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Fig. 4. Thermodenaturation of pantothenate kinases (PANK3). Thermodenaturation of human PANK3 was monitored by DSF using SYPRO Orange (A), DSLS (B) and by DSF
using CPM (C). Human PANK3 was not amenable to DSF using SYPRO Orange dye due to a high ﬂuorescence background, and no transition was observed. However, in an
aggregation-based assay (DSLS), a deﬁned transition with a typical background was obtained. Replacing SYPRO Orange with CPM also produced a typical transition without
signiﬁcant ﬂuorescence background interference.
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ily bemonitoredbyDSFusingCPMor by differential static light scat-
tering (Fig. 4). Alexandrov et al. also reported the limitations of the
method, including the effect of pH on sensitivity and selectivity of
CPM, as well as the need to eliminate reducing agents from puriﬁed
proteins, and an increase in the ﬂuorescence background if the pro-
tein contains exposed cysteine residues in unstructured loops. Sim-
ilarly, CPMmay react with the cysteine residues in the active site of
enzymes and interfere with ligand binding. The authors alsoreported the application of CPM in generating isothermal denatur-
ation proﬁles of several proteins. The application of high throughput
isothermal denaturation in screening libraries of compounds using
Sypro Orange (Senisterra et al., 2008) and detecting small stability
differences betweenprotein variants byDSLS has also been reported
(Hong et al., 2007).
Another method to monitor protein denaturation is differential
static light scattering (DSLS), a label-free method in which aggre-
gation of unfolded proteins upon heat-denaturation is monitored
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The intensity of the scattered light is presented as arbitrary values
which, when plotted against the temperature, will result in plots
similar to typical thermodenaturation proﬁles (Figs. 2 and 4). The
inﬂection point of the sigmoid curve is called Tagg and is similar
to the Tm obtained by DSF (Senisterra et al., 2006; Vedadi et al.,
2006). DSLS measurements are performed using a StarGazer
instrument (Harbinger Biotechnology and Engineering Corpora-
tion) in 384-well clear bottom plates.
The majority of proteins are amenable to DSLS and DSF, and
both methods provide comparable data (Vedadi et al., 2006). How-
ever, DSF cannot be used with hydrophobic proteins due to high
ﬂuorescence backgrounds. On the other hand, some proteins (espe-
cially very small proteins) do not aggregate over short time scales
immediately upon denaturation and, therefore, may not be amena-
ble to DSLS. The possibility of adapting a variety of ﬂuorescence
plate readers, such as RT-PCR machines that are readily available
to researchers, and the ability to use commercially available soft-
ware such as XLﬁt (IDBS) to analyze the data from 384-well runs,Table 1
Comparison of methods that assess ligand binding.
Ligand
Screening
Method
Throughput Suitable
instruments
(examples)
Protein
requirement
Advantages
Differential
scanning
ﬂuorimetry
(DSF);
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96-well
format
96-well
format
384-well
format
384-well
format
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iCycler from
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LightCycler 480 II
from Roche
<5 lg/well – Independ
function
– High thr
Differential
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ﬂuorimetry
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CPM
4*
(expandable)
96**
Cary Eclipse
spectroﬂuorometer
Mx3005p™ from
Stratagene
<5 lg/well – Independ
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– Low ﬂuo
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proteins
– Potentia
Differential
static light
scattering
(DSLS)
384 StarGazer from
Harbinger
<10 lg/well – Independ
function
– Label-fre
– Applicab
proteins
– High thr
Surface plasmon
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low
Biacore
ProteOn XPR36;
Bio-Rad
Low lg
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– Real-tim
macrom
– KD deter
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low
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low mg
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macrom
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paramet
Circular
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(CD)
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JASCO
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High lg to
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unfoldin
(Tm shif
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compound
displacement
384 Synergy 4 from
BioTek
ViewLux from
PerkinElmer
Low lg/well – High thr
– Identiﬁe
a speciﬁ
– KD deter
macrom
* (Alexandrov et al. 2008).
** Test runs by the SGC lab.as well as the fact that such experiments can be performed on pro-
teins regardless of their function, makes DSF an attractive 1st
choice for protein characterization (Niesen et al., 2007). These
experiments are typically performed in a 384-well format and each
run, including the data analysis, takes less than two hours, thereby
providing a screening capacity of more than 2000 data points per
instrument per day. Screening soluble proteins for ligand binding
is the primary application of DSF and DSLS. Recently, we also
established that DSLS can also be used to screen membrane pro-
teins (Senisterra et al., 2010). The speciﬁcation and capabilities of
DSLS and DSF and other methods of screening for ligand binding
are compared in table 1.
Although DTm or DTagg values can be used for estimating the
afﬁnity of compounds for the majority of proteins, one should be
careful in using these values to compare protein afﬁnities for com-
pounds with different physico-chemical properties (Holdgate and
Ward 2005; Waldron and Murphy, 2003). The Tm or Tagg shift
may not necessarily be the same for compounds with the same
afﬁnity, and it is dependent on the contributions of enthalpy andLimitations
ent of protein
oughput
– Sensitive to hydrophobicity of proteins
(high ﬂuorescence background)
– Sensitive to compound ﬂuorescence
ent of protein
rescence background
le to membrane
lly high throughput
– Limited to Cys-containing proteins
– Solvent accessible Cys residues contribute to
background
– Sensitive to presence of reducing agent
– effect of pH on sensitivity and selectivity of CPM
– Sensitive to compound ﬂuorescence
ent of protein
e
le to membrane
oughput
– Not applicable to reversible protein denaturation
– Proteins that do not aggregate over short time scale
immediately upon denaturation may not be amena-
ble
to DSLS
ent of protein
e on-and-off rates of
olecule interactions
mination for
olecule interactions
– Requires protein or ligand immobilization
– Relatively low throughput
ent of protein
mination for
olecule interactions
thermodynamic
ers
– High protein requirement
– Relatively low throughput
ent of protein
structural data
for assessing folding/
g and ligand binding
t)
– High protein requirement
– Relatively low throughput
oughput
s ligands that bind to
c binding site
mination for
olecule interactions
– Need a labeled ligand
– Indirect measurement of binding
– Sensitive to compound ﬂuorescence
112 M. Vedadi et al. / Journal of Structural Biology 172 (2010) 107–119entropy to binding. Larger Tm shifts are observed for more entropi-
cally driven (e.g., hydrophobic) ligand binding. Also a range of
different afﬁnities, with different entropic and enthalpic compo-
nents, might result in the same change in Tm. There are cases in
which a compound may bind tightly but no change in Tm would
be detectable. For example, tight enthalpy-driven binding of a
compound to the native state of a protein could potentially be
masked by weaker, entropy-driven binding to the denatured state.
It is even possible that the protein may exhibit a decrease in Tm in
the presence of a ligand, even though the compound binds tightly
to the native state (Holdgate and Ward 2005; Waldron and Mur-
phy, 2003). In such cases, the use of other methods to detect bind-
ing, such as ITC, would be more informative. The use of enthalpy of
binding as a tool for selecting compounds in lead discovery and
aiding lead optimization has been proposed (Ladbury et al., 2010).
A variety of chemical libraries are prepared for ligand screening
in the SGC, some targeting speciﬁc families of proteins such as ki-
nases (Fedorov et al., 2007) and sulfotransferases (Allali-Hassani et
al., 2007), and some are designed to search for compounds with
physiological relevance (Vedadi et al., 2006; Wishart et al., 2009).
There are also commercially available libraries enriched for phar-
macologically active compounds such as the Prestwick Chemical
Library (www.prestwickchemical.com/index.php? pa = 26). Typi-
cally, a protein is screened against the libraries of compounds at
a single concentration, and the ‘‘hits” are conﬁrmed by repeating
the thermodenaturation experiment in the presence of an increas-
ing concentration of compound. Such screening can be employed
to test a limited number of compounds in order to investigate
the substrate speciﬁcity of an enzyme (Fig. 2) or to screen libraries
with a large number of compounds. The resulting chemical ﬁnger-
prints generated for different members of a family of proteins can
be used to investigate binding speciﬁcity, active site similarity and
selectivity of inhibitors (Allali-Hassani et al., 2007; Fedorov et al.,
2007; Liu et al., 2009). The chemical ﬁngerprint of an enzyme in
the presence and absence of the co-factor can also be compared
to obtain a more in-depth knowledge of the order of binding. These
data provide preliminary information on the mechanism of inhibi-
tion (Fig. 5), and they are a convenient prescreen for more detailed
enzymatic studies. Structure determination for more than 10% of
the proteins solved by the SGC was only possible in the presence
of ligands identiﬁed by such screening (Vedadi et al., 2006). Other45
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Fig. 5. Protein chemical ﬁngerprints. Chemical ﬁngerprints of sulfotransferase 1C3 (
50-phosphate (PAP) are presented. Cytosolic sulfotransferases (SULTs) comprise a family o
50-phosphosulfate (PAPS) to an acceptor group of a variety of substrates. PAP is a produc
compounds both in the presence of a saturating concentration of PAP (10 mM) and in the
each histogram indicates the effect of a particular compound on stability of the protein
same compounds in the same order are represented in both horizontal lines. Each compo
ﬁgure. Abbreviations: APMPH: apomorphine, AMP-PNP: adenosine 50-(b,c-imido) triph
(6,8-dichloro-4-oxo-4H-chromen-3-ylmethylene)-hydrazide, and DBHBM: 3,5-dibromo
(Allali-Hassani et al. 2007).methods, such as ITC, peptide displacement and enzyme assays,
are routinely used in the SGC as secondary assays to conﬁrm com-
pounds identiﬁed by thermal denaturation methods.
In some cases, the proteins may not be amenable to DSF or
DSLS, and we have therefore employed other screening methods
such as the AlphaScreen™ assay (ampliﬁed luminescent proximity
homogeneous assay) to test compounds and screen relevant chem-
ical libraries (Wigle et al., 2010). AlphaScreen™ is a bead-based
technology that was designed to measure the proximity of donor
and acceptor beads conjugated to biomolecules of interest (Ullman
et al., 1994). Alpha donor beads contain a photosensitizer (phtha-
locyanine), which converts ambient oxygen to an excited form of
O2 (singlet oxygen) upon illumination at 680 nm. Within its 4-lsec
half-life, singlet oxygen can diffuse approximately 200 nm in solu-
tion. This enables the excitation of the Alpha acceptor beads.
AlphaScreen was originally designed as a direct homogeneous sub-
stitute for the ELISA immunoassay method where the coating, cap-
ture and wash steps are replaced by a pair of detection beads
capable of recognizing two unique sites on the analyte of interest.
As an example, the methylation of histone peptide substrates can
be easily detected by speciﬁc methyllysine primary antibody-
based interactions, in conjunction with streptavidin-coated donor
and secondary antibody-coated acceptor AlphaScreen beads (Quinn
2010).3. Screening for optimum buffer conditions
In large-scale protein expression and puriﬁcation efforts, a pres-
elected standard buffer condition is traditionally used for all pro-
teins in the initial puriﬁcation attempts. However, proteins have
diverse physical properties, and their solubility and stability de-
pend on the buffer conditions used during puriﬁcation and storage.
Considerable numbers of proteins show some degree of aggrega-
tion and precipitation during puriﬁcation and storage (referred to
here as problematic proteins). Frequently, these proteins are also
difﬁcult to concentrate. Altering the composition of the buffer used
during puriﬁcation can signiﬁcantly inﬂuence protein stability. For
example, the half-life of the DnaB protein from Escherichia coli was
dramatically increased using an optimized buffer condition that
was identiﬁed through screening a series of puriﬁcation buffers+ PAP
- PAPPLPNorepinephrine
AMPPNP
+ PAP
- PAP
SULT 1C3) in the presence (+PAP) and absence (-PAP) of 30-phosphoadenosine
f enzymes that catalyze the transfer of a sulfonate group from 30-phosphoadenosine
t of the reaction. SULT 1C3 was screened in duplicate by DSLS against a library of 90
absence of PAP. The horizontal line in each case marks the Tagg/Tm of the protein, and
. Two histograms exist for each compound, representing the data in duplicate. The
und that was identiﬁed as a binder is indicated by the name of the compound in the
osphate, PLP: pyridoxal 5’-phosphate, DBHB: 3,5-dibromo-4-hydroxy-benzoic acid
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Fig. 6. Mining the screening data. The proteins from malaria parasites were
screened for stability by DSLS in buffers at pH 6 (N), 7 (h), 8 () and 9 (s) in order to
ﬁnd the optimum buffer condition for each protein. A higher stability and possibly
better solubility in the optimum buffer condition is very helpful in long-term
protein storage and when the protein is subject to lengthy processes such as
crystallization or multi-step protein puriﬁcations. Many of these proteins showed
signiﬁcant changes in stability in different buffers, indicating the necessity of such a
screening platform. Such large-scale screening also provides an opportunity to
analyze the data in search for correlations between physico-chemical properties of
proteins and optimum buffer conditions. This type of analysis could potentially help
predict what buffer condition to use for each group of proteins based on their
physico-chemical characteristics to reduce protein precipitation due to partial
unfolding. Proteins are arbitrarily numbered from 1 to 111 and have been plotted in
order from the least stable to the most stable protein. The isoelectric point (pI),
molecular weight (MW), and percentages of positively and negatively charged
residues are also plotted in the same order for the same proteins. Most proteins
with no thermodenaturation transitions (top, right-hand side) appear to have lower
molecular weights. Assuming that these proteins are not extremely stable in those
conditions, the data suggest that very small proteins may not aggregate over short
time scales immediately upon denaturation and may be less amenable to DSLS.
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in the presence of a ligand (co-factor, ion, etc.) to promote proper
conformational changes or folding and to thereby increase solubil-
ity. For example, the expression of the recombinant human 11b-
hydroxysteroid dehydrogenase type 1 in E. coli was increased by
more than one order of magnitude in the presence of an inhibitor
(Elleby et al., 2004).
In addition to screening for ligands, we adapted a combination
of dynamic light scattering (DLS) and thermodenaturation-based
screening at the SGC in order to ﬁnd optimum buffer conditions
that increase the solubility and stability of problematic proteins.
DLS is very sensitive in detecting small particles in solution and
can differentiate between non-aggregated proteins and proteins
that form ‘‘soluble aggregates” or oligomers in solution. On the
other hand, differential scanning ﬂuorimetry (DSF) and differential
static light scattering (DSLS) allow evaluation of the effect of buffer
conditions on protein stability. Unlike DLS, DSLS is only sensitive to
insoluble aggregates produced during protein precipitation and
denaturation. The recombinant proteins may require several puri-
ﬁcation steps, which may take many hours. Furthermore, they may
be stored for lengthy periods before being used and thus undergo a
freeze–thaw process, and they are almost always subject to
lengthy protocols such as crystallization screening and kinetic
studies. It is therefore very helpful to select a buffer condition that
makes the protein not only more soluble but also more stable. Con-
ditions that make a protein more stable sometimes render im-
proved solubility as well.
We previously reported that by using thermodenaturation
methods to screen for stability, a buffer condition was identiﬁed
in 50% of the cases that stabilized the protein by at least 4 C com-
pared with the original buffer (HEPES buffer, pH 7.5, 150 mMNaCl)
(Vedadi et al., 2006). Most proteins were also stabilized in this as-
say by the addition of higher concentrations of NaCl. Only 27% of
proteins were more stable at lower NaCl concentrations. In some
instances, the identiﬁcation of a stabilizing solution increased the
ability to purify, concentrate or crystallize the protein (Vedadi
et al., 2006). Using buffers and additives identiﬁed by DSF, Ericsson
et al., reported a twofold increase in the number of crystallization
leads compared with screening in the absence of the additives
(Ericsson et al., 2006). Buffer optimization to improve puriﬁcation
yield and protein quality has also been reported (Mezzasalma
et al., 2007).
In search for optimum buffer conditions, more than 100 malar-
ial proteins from different Plasmodium species were screened for
stability by DSLS at various pHs (6, 7, 8 and 9). This provided an
opportunity to seek possible correlations between protein stability
related to the pH of a buffer and physical properties of these pro-
teins (Fig. 6). About 25% of the proteins showed no thermodenatur-
ation transition up to 80 C in any buffer. Interestingly, a signiﬁcant
number of the remaining proteins (>50%) appeared to be most sta-
ble in an alkaline condition, versus only about 20% that were more
stable in an acidic buffer (pH 6). The rest of the proteins were
either most stable at neutral pH or showed no preference for any
speciﬁc buffer. Although no correlation was observed between
the isoelectric points of the proteins and their stability, there
may be a weak correlation between their stability and their molec-
ular weight and percentage of charged residues. The proteins that
showed no transition in all or some buffer conditions were often
small proteins (Fig. 6), raising the possibility that some very small
proteins may not aggregate over short time scales and would
therefore not be amenable to DSLS.
Dynamic light scattering (DLS) has long been used to identify
optimal conditions for protein crystallization (Ferre-D’Amare and
Burley 1994; Kadima et al., 1990; Moreno and Bolan~os-Garcı´a
2000; Skouri et al., 1991; Zulauf 1992). To identify the optimum
buffer conditions that reduce aggregation of problematic proteins,
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tions that include variations of pH, salt, and additives. Since we
adapted this protocol for screening problematic proteins by DLS,
analyzing the data to identify an optimum buffer condition from
a high number of screened conditions and evaluating polydisper-
sity or particle size distributions for each sample from the DLS
screening output turned out to be difﬁcult and time consuming.
Alternatively, we took an unconventional approach to analyzing
the data that helped us ﬁnd optimum buffer conditions for proteins
more quickly. We chose to focus on selecting conditions of lower
scattered intensity as a measure of minimum aggregation (the
intensity of scattered light is proportional to the square of the mass
of the solute particle). The DLS instrument (DynaPro™, Wyatt
Technologies) contains a feature that automatically shuts down
the detector to protect it from damage when a sample is aggre-
gated and the intensity of the light scattered is too high. The
dynamics software that controls the data collection automatically
adjusts the power of the laser to prevent loss of data due to this
protection feature. Therefore, the higher the laser power and the
lower the intensity, the more soluble the protein is in solution.
The percentage of laser power and the beam intensity for all con-
ditions can be quickly exported into Excel and ranked.
This approach has been used to identify better conditions to
purify a variety of proteins. As an example, a variant of the sulfo-
transferase SULT2B1 (D191 N) was puriﬁed, concentrated and
screened only after the optimum buffer condition reduced protein
aggregation. The wild-type SULT2B1 protein is an easy-to-purify
protein with a high yield in HEPES buffer (10 mM HEPES,
500 mM NaCl, pH 7.5), and it was concentrated to 18 mg/ml. Un-
like the wild-type, the D191 N mutant that was puriﬁed under
the same conditions precipitated during the concentration proce-
dure. The protein was screened against 96 different buffer condi-
tions by DLS after removing the precipitate. It was observed that
in all conditions there was some degree of aggregation, and the la-
ser power was lower than the expected 100% for the protein con-
centration employed (0.2 mg/ml). However, we found a condition
(100 mM sodium citrate, 100 mM NaCl, pH 6.5) in which the inten-
sity of the laser was the highest (65%). Such a protocol typically re-
quires less than two hours to complete. Using this new condition,
we were able to concentrate the protein to 10 mg/ml. Subse-
quently, it was possible to screen the protein by DSLS for ligand
binding, which resulted in identiﬁcation of ligands with stabiliza-
tion effects of about 10 C at 1 mM. It is worth mentioning that this
approach is not used to decide what protein should or should not
be put through the crystallization process. It is simply used to iden-
tify buffer conditions that keep the protein more soluble, providing
an opportunity to further concentrate the protein, and enabling
crystallization screening.
Size exclusion chromatography (SEC) is another method that
can be used for estimating the sizes of macromolecules and the
separation and quantitation of the non-covalent aggregate from
the non-aggregated protein populations based on size (originally
developed by (Porath and Flodin, 1959). This method is useful in
assessing protein truncation, fragmentation and aggregation. It is
an inexpensive technique with a potentially high sample through-
put using a simple physical separation mechanism. In most cases,
SEC works well, achieving good size separations and valid aggrega-
tion information. However, such results may require the validation
of an orthogonal method to ensure that weakly associated aggre-
gates are detected. Additionally, typical column-related problems
may occur. The separation of non-covalent aggregation by a
mechanism based solely on species size occurs only when there
is no interaction between the solute and the column matrix.
Although high performance SEC columns are designed to minimize
non-speciﬁc interactions, most modern SEC columns are weakly
anionic (negatively charged) and slightly hydrophobic, resultingin deviations from ideal size exclusion behavior (Chirino and
Mire-Sluis, 2004; Clodfelter et al., 1999; Kamberi et al., 2004).
The need to run many samples often results in the use of a mobile
phase that is signiﬁcantly different from the sample buffers.
Changing mobile phase buffers for each protein sample would be
impractical and time consuming. Therefore, SEC is less desirable
for screening for optimum buffer conditions that reduce aggrega-
tion. Also, the need for upfront sample preparation to prevent
column clogging (e.g., sample ﬁltration) is not only time consum-
ing, but it can also alter the amount and the size distribution of
aggregation in the initial sample. Analytical ultracentrifugation
(AUC) is another method that can accurately detect aggregates,
and it is also sensitive to molecular shape (Berkowitz, 2006). This
method has widely been used for determining the oligomerization
state of proteins and estimating dissociation constants (Coutandin
et al., 2009; Elkins et al., 2009; Pike et al., 2008), as well as for
assessing the effect of buffers in increasing solubility and monodis-
persity of proteins (Bullock et al., 2009). However, AUC is time
consuming and would be suitable for conﬁrming data obtained
from high throughput methods of screening.4. Protein–protein interaction and peptide binding
4.1. Screening for binding peptides
The importance of protein–protein interactions has been widely
recognized and investigated (Costa and Cesareni 2008). A major
mechanism for protein–protein interactions is the binding of a
globular protein or domain to a short peptide region of an interac-
tion partner. Such protein-peptide interactions are highly enriched
in signaling networks and are frequently mediated (positively or
negatively) by post-translational modiﬁcations (PTMs), such as
phosphorylation, acetylation and methylation (Pawson and Nash,
2003; Pawson et al., 2002; Santos-Rosa and Caldas, 2005; Seet et
al., 2006). The generation of an appropriately modiﬁed binding
partner for biochemical studies is usually best achieved by syn-
thetic techniques.
Synthesizing and purifying peptides using the standard peptide
synthesis technology as an alternative to full-length proteins for
testing their substrate speciﬁcity are relatively slow and expensive
processes. Several modiﬁed peptide synthesis procedures have
been developed to address this problem (Frank, 2002; Geysen et
al., 1984; Houghten, 1985; Pellois et al., 2002). Among these, the
SPOT-synthesis technique is easy to handle and can be performed
with minimum intervention (Frank, 2002; Kramer and Schneider-
Mergener, 1998). This technique involves synthesizing and immo-
bilizing peptides on a membrane which is suitable for mapping the
protein–protein contact sites and proﬁling substrate speciﬁcity of
enzymes (e.g., protein kinases, histone methyltransferases, etc.).
The quantity and amino acid composition of the peptides can be
easily modiﬁed, and detection of peptide–protein interactions in-
volves simple blotting. The efﬁciency and quality of the synthesis
of peptides on the membrane using standard L-amino acids have
been validated by mass spectrometry (Frank, 2002; Hilpert et al.,
2007). This method has been shown to be sensitive in detecting
antibody-peptide interactions with KD values as high as 1 mM
(Kramer et al., 1999; Landgraf et al., 2004; Weiser et al., 2005).
The ability to include modiﬁed amino acids in immobilized pep-
tides provides an ideal tool for testing proteins that are involved
in PTMs.
In the SGC, we have established a peptide screening platform
where proteins are screened against custom-made membranes
with up to 600 immobilized peptides on each membrane (Nady
et al., 2008). Desired peptides (8–20 residues long) are synthesized
on and covalently linked to a modiﬁed cellulose membrane with a
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Fig. 7. Screening for peptide-protein interactions using immobilized peptides on
cellulose membranes. A total of 180 peptides were synthesized on a membrane.
These peptides were designed based on an amino acid sequence of histone tails and
included possible post-translational modiﬁcations such as acetylation and mono-,
di-, and tri-methylation of lysines, and phosphorylation of serine and threonine
residues. Histone methyltransferases (HMTs) and histone acetyltransferases (HATs)
are responsible for methylation and acetylation of lysine residues on histone tails,
which consequently affect chromatin condensation state and subsequent gene
expression. In this experiment, a HMT was screened against this set of peptides,
which were selected speciﬁcally for this methyltransferase, and poly-histidine
peptides (12-mer) were also included as a positive control (pHis). The His-tagged
protein binds to interacting peptides, and the presence of the protein can be
detected by using anti-His antibodies (the HRP conjugate from Novagen was used in
this experiment). All steps of the protocol were also performed in parallel without
the addition of the enzyme as a control to eliminate false positives. Those spots that
appeared on the membrane only when the protein was added (E5 and E8) were
identiﬁed as hits (interacting peptides). Typically, the identiﬁed interacting
peptides will be synthesized in solution, labeled with ﬂuorescein, and their binding
afﬁnities will be further evaluated by ﬂuorescence polarization.
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sizer. This has the capacity to synthesize about 2400 peptides in
four days. Immobilized peptides are then screened in an overlay
assay to determine which peptides bind to the tested protein.
The membrane is extensively blocked with skim milk, incubated
with a His-tagged protein of interest, washed with phosphatebuffered saline/Tween, and developed via western blot analysis. For
example, screening a histone methyltransferase against a set of
180 peptides, shown in Figure 7, reveals that two speciﬁc peptides
(E5 and E8) are clearly interacting with the protein. Performing
the same experiment in the absence of the protein as a negative
control indicates that the observed intensities for E5 and E8 are
not artifacts. All three polyHis peptides that were used as positive
controls were detected as hits with signiﬁcant intensities (Fig. 7).
However, some low intensity peptide spots associated with the
experimental background are randomly present in both mem-
branes. The amount of His-tagged protein used and the time of sig-
nal development may be optimized to reduce the background
noise. The results of such screening are considered preliminary,
and positive hits need to be validated by secondary assays such
as ﬂuorescence polarization.
The ability to incorporate modiﬁed residues (methylated, phos-
phorylated, acetylated, etc.) in any position within a peptide pro-
vides an opportunity to mimic post-translational modiﬁcations of
proteins and to study the ways in which protein-peptide interac-
tions are altered by these modiﬁcations. The peptide array ap-
proach is particularly useful for cases such as interactions with
the natively disordered ‘‘histone tails” of nucleosomes, in which
multiple sequences, each with a variety of modiﬁcations and com-
binations of PTMs, need to be screened for interactions with poten-
tial binding partners (Nady et al., 2008). Alternatively, other
methods, such as the immobilization of glutathione S-transferase
(GST) proteins and subsequent screening against ﬂuorescently-
labeled methylated histone peptides (Kim et al., 2006), or the use
of biotinylated histone peptides for pull-down assays (Wysocka,
2006), have been used. However, these methods may not provide
the same throughput.
4.2. Fluorescence polarization
Fluorescence polarization (FP) was ﬁrst observed by Weigert in
1920 and later described by Perrin in 1926 (Collett and Schaefer,
2009). It is a well-established analytical technique that has been
employed in a variety of biophysical characterization experiments,
including the investigation of protein–protein, protein-peptide and
protein-oligonucleotide interactions (Jameson and Seifried, 1999;
LeTilly and Royer, 1993; Yu et al., 1996). FP-based immunoassay
methods have also been used for clinical diagnostics (Bittman
and Fischkoff, 1972; Chen and Potter 1992). FP-based screening
has been adapted for high throughput screening (Du et al., 2007;
Kawamoto et al., 2009; Reindl et al., 2009). An increase in the size
of the labeled molecule (e.g., a peptide) through its binding to an-
other macromolecule (in this case an interacting protein) affects its
motion in solution, which can be detected by ﬂuorescence
polarization.
We typically end-label the peptide with ﬂuorescein, which has a
ﬂuorescence lifetime shorter than 10 ns, allowing the changes in
polarized signal to be detected over a wider range of molecular
masses (Pope et al., 1999). The observed value of FP depends on
free and bound fractions of labeled molecules. Instruments such
as the Synergy 2 Microplate Reader (BioTek) or ViewLux ultraHTS
Microplate Imager (PerkinElmer) can be used for such FP experi-
ments. Our collection of peptides is N-terminally labeled with ﬂuo-
rescein and puriﬁed. The binding assays are performed in a 10-ll
volume at a constant labeled peptide concentration (usually
around 40 nM) by titrating the protein within a range of low to
high micromolar concentrations into appropriate buffer with
0.01% Triton X-100. The value of the measured FP is corrected by
subtracting the value corresponding to the labeled peptide in the
buffer (typically about 80 to 100 mP). To determine the approxi-
mate KD values, the data are ﬁtted to a hyperbolic function using
SigmaPlot

software (Fig. 8A).
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Fig. 8. Application of ﬂuorescence polarization in assessing peptide binding and
screening for compounds. An 11-mer ﬂuorescein-labeled peptide, similar to the ﬁrst
11 residues of the C-terminal of the histone H3 that was dimethylated on lysine 4
(H3K4Me2) at 36 nM, was titrated with WDR5 from 30 nM to 30 lM. An increase in
the observed ﬂuorescence polarization (FP) signal was plotted against the WDR5
concentration (A). A KD value of 100 ± 9 nM was calculated by ﬁtting the data to a
hyperbolic equation using SigmaPlot 9. WDR5 (WD repeat domain 5), a WD-40
domain protein, is known to bind to the N-terminal of H3when Lys4 is dimethylated
(K4me2). This is a marker for further methylation by a methyltransferase MLL1
(mixed lineage leukemia-1). The 3D structure and mechanism of binding for this
protein have been extensively studied (Couture et al. 2006; Han et al. 2006;
Ruthenburg et al. 2006; Schuetz et al. 2006). Reproducibility of the FP signal and the
possibility of peptide displacement were tested within a 384-well plate by repeating
the experiment 100 times using the condition that produced themaximum FP signal
(0.5 lM WDR5 and 36 nM ﬂuorescein-labeled peptide; F-H3K4Me2) and the same
numberofpositive controls (0.5 lMWDR5 + 36nMF-H3K4Me2displacedby250 lM
unlabeled H3K4Me2) (B). Excellent reproducibility was observed with a Z’-factor of
0.77, indicating that this methodology can be used for screening compounds. FP
experiments were carried out in 100 mM potassium phosphate buffer (pH 8, 0.01%
Triton X-100). In a peptide displacement experiment (C), the ability of a compound
(.) to displace the F-H3K4Me2 from theWDR5binding sitewas conﬁrmed. Similarly,
a positive control (unlabeled H3K4Me2, d) also displaced the labeled peptide.
Monitoring of the change in FP signals due to peptide displacement is an efﬁcient
method of screening for compounds that interrupt protein–protein interactions.
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In cases in which the peptides are known to bind to proteins,
such as those interacting with histones (e.g., histone methyltrans-
ferases, acetyltransferases), the optimum FP signal can be used to
screen for ligands. The compounds that bind to the same site as
the binding peptide and can disrupt the protein-peptide interac-
tion will typically displace the ﬂuorescein-labeled peptide, result-
ing in a decrease in the initial FP signal. In the presence of all
other compounds (no binding), the FP signal will remain un-
changed. The effect of the compounds can be conﬁrmed when
the experiment is performed in the presence of different concen-
trations of compounds. This protocol can be applied in a 384-well
format with a Z’-factor (Zhang et al., 1999) of 0.77 (Fig. 8B and C).5. Other biophysical characterization methods
Nuclearmagnetic resonance (NMR) is another biophysicalmeth-
od that can be used to study protein–ligand interactions (Baldwin
and Kay, 2009; Coles et al., 2003; Skinner and Laurence, 2008).
NMR can be used to evaluate the structural, thermodynamic and
kinetic aspects of a binding reaction. Upon the interaction of a small
molecule ligand with a protein target, a perturbation of the NMR
spectrum occurs, and the detection of the perturbation is the basis
of ligand binding analysis by NMR. The unique properties of small
compounds andmacromolecules allow selective detection of either
the protein target or ligand. Within our platform, we use NMR
screening as a secondary screen to conﬁrm some ligand binding
interactions (Fig. 1).
Many other biophysical techniques can also be very useful for
characterizing individual proteins and, consequently, for aiding
structural genomics efforts. However, a discussion of all these
methods is beyond the scope of this review.6. Concluding remarks
Over 35% of the protein structures deposited in the protein
databank (PDB) by the SGC have been co-crystallized with small
molecules that were identiﬁed through screening or were pre-
dicted to bind based on the expected function of the protein, and
conﬁrmed through characterization of the puriﬁed protein. In
about 10% of all structures determined by the SGC, the determina-
tion of the protein structures was made possible only by the pres-
ence of the identiﬁed ligands (Vedadi et al., 2006). In addition,
more than 50 structures have been determined in the presence
of peptides selected through protein screening and characteriza-
tion (Eryilmaz et al., 2009; Guo et al., 2009; Min et al., 2007;
Schuetz et al., 2006). This platform has also been employed in a
quest to identify chemical probes to explore the variety of ways
in which proteins can be modiﬁed following translation. Such ef-
forts have led to a rapid identiﬁcation of the most potent inhibitor
reported to date for the histone methyltransferase G9a (Liu et al.,
2009) (PDB ID; 3K5 K). In addition, the components of this platform
that were put together through the development of new large-
scale characterization methods (Nady et al., 2008; Niesen et al.
2007; Senisterra et al., 2010; Senisterra et al., 2006; Senisterra
et al., 2008; Vedadi et al., 2006) have helped in the characterization
of large numbers of proteins (www.thesgc.org/publications/),
including many variants of human proteins (Allali-Hassani et al.,
2009; Hong et al., 2007).
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